Beta Drugs Limited is a public limited company incorporated in September 2005, headquartered in Panchkula, and operates within the pharmaceutical sector with a primary focus on developing and marketing oncology and dermatology medicines. The company manufactures and sells a wide range of therapeutics, including drugs for breast, blood, lung, lymph, testicular, and ovarian cancers. In recent developments from 2025, CRISIL revised the company’s rating outlook to ‘Positive’ in August 2025, supported by sustained revenue growth, healthy operating margins, and volumetric expansion across domestic and export markets. Furthermore, the company expanded its international footprint in 2025 by filing multiple dossiers across regulated markets following successful international audits, alongside forming strategic distribution and in-licensing agreements.

For the financial year ending March 31, 2025, Beta Drugs Limited reported a strong operational performance with revenues reaching INR 362 crores, representing a healthy growth rate compared to the previous fiscal year. The reported profit after tax (PAT) for fiscal 2025 stood at INR 44.6 crores with a PAT margin of 12.3%, driven by robust demand in its branded and export segments. The company maintains a strong financial risk profile with low reliance on external debt, healthy net cash accruals, and substantial liquidity reserves. Prominent institutional and public stakeholders maintain positions within the company, while the promoter group continues to lead strategic expansions across domestic and international healthcare markets.